Literature DB >> 18542103

Statins and prostate cancer prevention: where we are now, and future directions.

Teemu J Murtola1, Tapio Visakorpi, Jorma Lahtela, Heimo Syvälä, Teuvo Lj Tammela.   

Abstract

Statins are cholesterol-lowering drugs that are widely used to prevent and treat atherosclerotic cardiovascular disease. Recent research from both in vitro and in vivo studies suggests that there is an association between the use of statins and a reduction in the incidence of and mortality from prostate cancer. Several mechanisms of action that might bring about these beneficial effects of statins have been proposed, most of which include direct effects of statins on intracellular signaling. In this Review we discuss the current knowledge on the use of statins to prevent prostate cancer. We will also look at future directions for clinical research on this topic.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18542103     DOI: 10.1038/ncpuro1146

Source DB:  PubMed          Journal:  Nat Clin Pract Urol        ISSN: 1743-4270


  23 in total

1.  Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells.

Authors:  Wen-Chin Huang; Xiangyan Li; Jian Liu; Jentai Lin; Leland W K Chung
Journal:  Mol Cancer Res       Date:  2011-11-07       Impact factor: 5.852

2.  mTORC2 is required for proliferation and survival of TSC2-null cells.

Authors:  Elena A Goncharova; Dmitry A Goncharov; Hua Li; Wittaya Pimtong; Stephen Lu; Irene Khavin; Vera P Krymskaya
Journal:  Mol Cell Biol       Date:  2011-04-11       Impact factor: 4.272

3.  Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins.

Authors:  Mohana Roy; Hsing-Jien Kung; Paramita M Ghosh
Journal:  Am J Cancer Res       Date:  2011-03-28       Impact factor: 6.166

Review 4.  Cholesterol as a potential target for castration-resistant prostate cancer.

Authors:  Alexis L Twiddy; Carlos G Leon; Kishor M Wasan
Journal:  Pharm Res       Date:  2010-08-04       Impact factor: 4.200

Review 5.  Metabolic alterations and targeted therapies in prostate cancer.

Authors:  Richard Flavin; Giorgia Zadra; Massimo Loda
Journal:  J Pathol       Date:  2010-11-16       Impact factor: 7.996

6.  Statin use and fatal prostate cancer: a matched case-control study.

Authors:  Stephen W Marcella; Alice David; Pamela A Ohman-Strickland; Jeffery Carson; George G Rhoads
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

Review 7.  New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK.

Authors:  Giorgia Zadra; Carmen Priolo; Akash Patnaik; Massimo Loda
Journal:  Clin Cancer Res       Date:  2010-04-27       Impact factor: 12.531

Review 8.  How low an LDL-C should we go with statin therapy?

Authors:  William J Kostis
Journal:  Curr Atheroscler Rep       Date:  2014-02       Impact factor: 5.113

9.  Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort.

Authors:  Julio E Celis; Teresa Cabezón; José M A Moreira; Pavel Gromov; Irina Gromova; Vera Timmermans-Wielenga; Takuji Iwase; Futoshi Akiyama; Naoko Honma; Fritz Rank
Journal:  Mol Oncol       Date:  2009-02-03       Impact factor: 6.603

10.  A chemical biology screen reveals a role for Rab21-mediated control of actomyosin contractility in fibroblast-driven cancer invasion.

Authors:  S Hooper; C Gaggioli; E Sahai
Journal:  Br J Cancer       Date:  2009-12-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.